Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

155.92 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Dogs Of The Dow: How You Can Get Dividend Stocks With Yields Up To 6.3%
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields. 
Via Benzinga
Topics Stocks
Johnson & Johnson's Drug Discount Plan Gets Thrown Out In Court
A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent. 
Via Benzinga
HDV Is a Popular Dividend ETF for Passive Income. But Is It the Best?
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
12 Analysts Have This To Say About Johnson & Johnson
Via Benzinga
FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning
The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group. 
Via Stocktwits
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Johnson & Johnson Is Great. Here's Why You Shouldn't Buy It.
Via The Motley Fool
Topics Lawsuit Supply Chain
Want Decades of Passive Income? 5 Stocks to Buy Now and Hold Forever
Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them. 
Via The Motley Fool
How Earle Dickson Healed Wound Care With The Band-Aid
When Earle Dickson (1892-1961) invented the Band-Aid, treatments for minor cuts and scrapes were dicey. He changed that. 
Via Investor's Business Daily
5 Dividend Stocks Poised to Profit From the AI Efficiency Boom
Via The Motley Fool
Topics Artificial Intelligence
Donald Trump Jr. Joins Mark Cuban In Slamming Elizabeth Warren on Healthcare Pricing
Donald Trump Jr. has joined Mark Cuban in publicly voicing disapproval of Sen. Elizabeth Warren's approach to healthcare pricing. 
Via Benzinga
Topics Government
Johnson & Johnson Unusual Options Activity For June 20
Via Benzinga
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices. 
Via Benzinga
2 Dividend Stocks to Buy and Never Sell
Via The Motley Fool
Topics Lawsuit
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson’s Q1 Earnings Call: Our Top 5 Analyst Questions
Johnson & Johnson’s first quarter results reflected a steady performance, with the company surpassing Wall Street’s revenue and adjusted profit expectations. Management credited the diversified... 
Via StockStory
Topics Earnings World Trade
Elizabeth Warren, Jan Schakowsky Reportedly Seek Answers From Pfizer, Amgen, And Others On Low Federal Tax Bills
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such... 
Via Stocktwits
Topics Government
Johnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth Considering
Johnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors. 
Via Chartmill
Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Stock Instead?
Via The Motley Fool
Topics Lawsuit
If I Could Invest $1,000 in Any Growth Stock, It Would Be This One
Via The Motley Fool
Topics Artificial Intelligence Economy Government
5 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Steady growth and dividend increases over decades can make investors remarkably wealthy. 
Via The Motley Fool
Topics Economy
Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know
Via Benzinga
3 Top Dividend Stocks Analysts Are Bullish on Right Now
With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support 
Via MarketBeat
Topics ETFs
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Johnson & Johnson Highlights Multiple Blood Cancer Trial Data At ASCO Presentation
Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple myeloma patients. 
Via Benzinga
5 Cheap Stocks to Buy in June
These stocks are ready for a summer surge. 
Via The Motley Fool
Top 3 Reasons Savvy Investors Are Buying Johnson & Johnson Stock While Others Panic Over Lawsuits
For long-term investors looking for both stability and innovation in the healthcare space, JNJ is a rare combination of both. 
Via Talk Markets
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted. 
Via Investor's Business Daily
3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row
Via The Motley Fool
Topics Bonds
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.